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responsibility of XAbstract Liquid chromatography (LC) is considered by many as a mature technique. Nonetheless,
LC technology continues to evolve driven by the need for high-throughput and high-resolution
analyses. Over the past several years, small particle size packing materials have been introduced by
several column manufacturers to enable fast and efﬁcient LC separations. Several examples of
pharmaceutical analyses, including impurity proﬁling of taxanes and atracurium besylate,
in-process testing of peptides in injectable dosage form, using sub-2 mm column technology are
presented in this paper, demonstrating some of the capabilities and limitations of the technology.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ease of use, adaptability to a wide range of detectors, availability
of a wide selection of stationary phases, its high resolving powerersity. Production and hosting by E
.004
651 1716x213;
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evard du Parc Technologique,
ens, Montre´al, QC H4S 1X6,
i’an Jiaotong University.and speed of analysis have made the use of modern liquid
chromatography (LC) very popular in the pharmaceutical indus-
try. Liquid chromatography is typically employed throughout the
entire pharmaceutical development process, from drug discovery
to raw material analysis, impurity proﬁling, stability studies and
ﬁnal product testing [1–3]. The development of LC methods for
analysis of drugs and their related substances is typically a time-
consuming process in an analytical laboratory. Therefore, separa-
tion scientists are continually driven towards the use of more
efﬁcient LC technology to speed up the method development and
validation process, as well as productivity in quality control
laboratories. Efﬁciency and speed of analysis become particularly
important while performing in-process pharmaceutical testing, a
necessary but time-consuming step to achieve high quality
standards in pharmaceutical product manufacturing [4,5].
Over the years, LC packing materials have evolved from
irregular shaped 10 mm silica particles to small spherical particles,
which are now less than 2 mm in diameter [6]. Spherical smalllsevier B.V. All rights reserved.
Testing drugs for injection by fast liquid chromatography 373particles can be packed more uniformly and homogeneously than
their irregular shaped counterparts, thus providing better efﬁ-
ciency and resolution for chromatographic separations.
However column permeability tends to decrease signiﬁcantly,
which is accompanied with an increase in column back pressure
[1,7]. High back pressure requires use of high-pressure LC
systems allowing operation that exceeds 400 bars. The use of
much shorter LC columns (o50 cm in length) at low ﬂow rates,
or the use of high separation temperatures to reduce mobile
phase viscosity may alternatively be used to reduce back
pressure, often at the cost of adequate separation efﬁciency
[6,8]. Although short columns with small particles provide rapid
LC separations, the column plate number is not always sufﬁcient
to allow complex multi-components analysis. In this paper,
several examples of pharmaceutical analyses, including impurity
proﬁling of taxanes and atracurium besylate, in-process testing of
peptides in injectable dosage form, using sub-2 mm column
technology will be presented, demonstrating some of the cap-
abilities and limitations of the technology.2. Materials and method
The experimental results reported in this paper were obtained on
Waters Acquity UPLCs (Milford, MA, USA) systems with
either a Photodiode Array Detector or tunable UV (TUV)
detector. The ﬁrst example of application of a sub-2 mm column
with a high pressure LC system to drug compound impurity
proﬁling involved the use of an Acquity UPLCs BEH C18,
100 mm 2.1 mm column with 1.7 mm hybrid silica particles
(Waters, Milford, MA, USA). The second example involved a
Zorbax Eclipse XDB-C18, 50 mm 4.6 mm column with 1.8 mm
particle size (Agilent Technologies, Santa Clara, CA, USA).
Analyses of peptides were performed on an Acquity UPLCs
BEH C18, 50 mm 2.1 mm column with 1.7 mm hybrid silica
particles, an Acquity UPLCs BEH 300 C18, 50 mm 2.1 mm
column with 1.7 mm hybrid silica particles with 300 A˚ pores, and
a Kinetexs C18, 100 mm 2.1 mm column with 1.7 mm core-
shell particles from Phenomenex (Torrance, CA, USA). High-
quality HPLC grade reagents and solvents were used throughout
this study. Mobile phases and samples were ﬁltered on 0.2 mm
GHP membrane and syringe ﬁlters (Pall Corporation, Port
Washington, NY, USA).Figure 1 Example of chromatographic separation of a taxane from
BEH C18 column (100 mm 2.1 mm), using a water/acetonitrile grad3. Results and discussion
3.1. Impurity proﬁling of drug substances and products with
sub-2 mm LC columns
Impurity and degradation proﬁling is an integral part of the
pharmaceutical quality control of drug substances and pro-
ducts. Impurity proﬁling often requires the use of longer LC
columns, along with a mobile phase gradient [9,10]. A typical
example involves the impurity proﬁling of an analog of
Taxols requiring the use of a 250-mm YMCTM ODS-AQ
column with a water/acetonitrile gradient, to achieve the
chromatographic separation of the taxane drug substance
from its many impurities [11]. Such a challenging separation
may take upto 90 min per sample injection, including mobile
phase gradient and column re-equilibration.
Use of conventional LC is excessively time-consuming and
could not practically be used for process testing during
pharmaceutical manufacturing, which typically requires rapid
testing methodologies. A Waters Acquity UPLCs BEH C18
column with 1.7 mm silica hybrid particles was used advanta-
geously to achieve a 7-fold reduction in analysis time (Fig. 1).
An equivalent gradient separation was achieved in 10 min with
a sub-2 mm column [12], as compared to the 75 min run time
with the conventional 3 mm ODS-AQ column. Such a short
analysis run time with UPLC is much more compatible with
impurity proﬁling while performing in process testing.
For a typical analysis sequence requiring replicate injections
of blank, standard (for system suitability), and sample solu-
tions, this represents a signiﬁcant reduction in analysis time
and total volume of mobile phases consumed: 2.8 h of analysis
time for 12 injections and a total volume of mobile phases of
100 mL using the Acquity UPLC methodology, as compared
to 18 h of analysis time and more than 1 L of mobile phase
using the conventional LC method. This represents not only a
signiﬁcant gain in efﬁciency, but also a signiﬁcant reduction in
operating costs for solvents used to prepare mobile phases and
a reduction in waste disposal.
Another example of a challenging LC separation using a
sub-2 mm column involves the impurity and degradation
proﬁling of atracurium besylate injection. Atracurium besylate
is a muscle relaxant used in anesthesia [13]. This molecule
has four chiral stereocenters and may occur in 10 differentknown impurities and degradants on a Waters Acquity UPLCs
ient at a ﬂow rate of 0.6 mL/min and UV detection at 228 nm.
M.-J. Rocheleau et al.374stereoisomeric forms, which makes impurity and degradation
proﬁling particularly challenging. Atracurium besylate injec-
tion is typically composed of 55.0–60.0% of the cis–cis isomer,
34.5–38.5% of the cis–trans isomer, and 5.0–6.5% of the
trans–trans isomer [14]. The most biologically active isomer is
the cis–cis isomer, also known as cisatracurium besylate [15].
The LC methodology in the United States Pharmacopeia
for atracurium besylate describes use of a 250 mm 4.6 mm
octadecylsilane base-deactivated column with a 30 min mobile
phase gradient at 1.0 mL/min [14]. However, we have demon-
strated that separation of the main isomers of atracurium
besylate can be readily achieved on a much shorter column,
50 mm 4.6 mm with a 1.8 mm C18 stationary phase, in one
third of the time with excellent resolution [16]; the resolution
between the trans–trans, cis–trans, and cis–cis isomers in
Fig. 2 is superior to 2.4. In addition to being more efﬁcient,
the dimensions of the Eclipse XDB column allow the fast LC
methodology for atracurium besylate to be operated on a
conventional system since the maximum column back pressure
does not exceed 300 bars. However, care must be taken to
minimize the internal volume of the system to reduce band
spreading and optimize peak resolution. It is important to
minimize connecting tubing as part of instrument optimiza-
tion, selecting the narrowest diameter and shortest length
tubing to prevent peak dispersion and loss in resolution.
Atracurium besylate injectable solution is refrigerated to
extend its shelf-life, as it degrades when exposed to room
temperature for just few hours. The solution is also particu-
larly sensitive to solution alkalinity [17,18]. Major degradants
of atracurium besylate include early-eluting laudanosine and a
monoquaternary acrylate of laudanosine besylate [18], which
elutes near the end of the mobile phase gradient. In Fig. 2, all
degradants eluted within 8 min allowing rapid assay and
degradation proﬁling. While laudanosine elutes at a relative
retention time (RRT) of 0.27 with respect to cisatracurium
besylate, monoquaternary laudanosine besylate elutes at RRT
1.26 after the cis–cis isomer of atracurium besylate. Therefore,
this methodology may not only be successfully applied to in
process assay of atracurium besylate, but also to the drug
product degradation proﬁling.3.2. Use of sub-2 mm column technology for in process testing
of drugs for injection
In process testing after compounding and formulating dosage
forms is becoming a common practice in manufacturing of
drugs for injection. Testing prior ﬁltration and vial ﬁlling
allows in process determination indicating whether or not the
ﬁnal products will meet speciﬁcations, allowing process opti-
mization and concentration adjustment to maintain high-
quality drug manufacturing. Speed of analysis is particularly
important while performing in process testing, since the
manufacturing process must be interrupted until results from
assay of the drug formulation are obtained. In process
pharmaceutical testing may take full advantage of the small
particle size column technology and high-pressure LC systems
to gain separation speed, while maintaining adequate efﬁ-
ciency and resolution.
Unfortunately, application of sub-2 mm column technology
is not always successful as exempliﬁed in the analysis of
octreotide acetate, a cyclic octapeptide mimicking naturalsomatostatin [19]. Separation of octreotide acetate from the
phenol preservative in a multi-dose formulation was achieved
using a Waters Acquity UPLCs BEH C18 column, in
combination with a rapid mobile phase gradient allowing in
process analysis to be performed in less than 3 min (Fig. 2).
The unidose formulation contains mannitol and sodium
acetate buffered with acetic acid at pH 4.2; the multi-
dose formulation additionally contains 0.5% of phenol
preservative.
Results from the dosage of the cyclic octapeptide in
representative batches of several formulations and strengths
are detailed in Table 1. Results from the Acquity UPLC
methodology and conventional LC methodology involving a
250 mm 4.6 mm YMCTM ODS-AQ column and a phospho-
ric acid–acetonitrile gradient are compared. Although sufﬁ-
ciently sensitive, inaccurate dosing of the octapeptide at low
dosage strength was systematically observed with the Acquity
UPLC methodology. While providing assay values consistent
with conventional LC at 200 and 500 mg/mL, inaccuracy
greater than 15% was observed in the peptide assay at
50 mg/L with a result lower than the speciﬁcation limit [16].
Despite evident gain in efﬁciency, inconsistencies in assay
values did not allow use of the UPLC methodology for in
process testing of octreotide acetate formulation.
Non-linear response is not uncommon in the analysis of
peptides and proteins. On-column system adsorption is parti-
cularly common in the analysis of proteins by capillary
electrophoresis [20]. The use of low pH, high ionic strength
buffers, and a higher sample concentration or injection volume
may help reduce the effect of adsorption on the analysis of
peptides and proteins by LC. While higher dosage strengths at
200 and 500 mg/mL are diluted by a factor of 4 and 10,
respectively, with 0.1% aqueous phosphoric acid, the low
dosage strength at 50 mg/mL must be injected without further
dilution at pH 4.2 to maintain adequate sensitivity. Adsorp-
tion of octreotide acetate from the low-strength unidose
formulation, injected at a higher pH, may explain the
inaccurate dosage results obtained by UPLC. Use of a large
pore Acquity UPLC BEH 300 C18 column did not help
improving the accuracy of the measurement at low-dose of
octreotide acetate, with measured inaccuracy of 12% as
compared to the theoretical concentration [16]. The low
internal volume of small particle size columns does not allow
injection volumes above a few microliters without risking
overloading the UPLC column. Use of conventional LC with
a 50 mL injection volume proved to be more reliable for the
determination of the low-dose peptide formulation.
Inaccurate measurement of the main impurity of the anti-
platelet peptide drug eptiﬁbatide was also observed using a
Phenomenex Kinetex C18 sub-2 mm column [16]. In Fig. 3, the
impurity eluting immediately after the main peak cannot be
detected when injected alone at a concentration of 0.5 mg/mL,
representing a concentration equivalent to 0.1% of the sample
concentration of eptiﬁbatide. Injected along with eptiﬁbatide,
the same impurity injected at the exact same concentration can
be easily detected and measured with a signal-to-noise ratio of
at least 10. Even at a concentration 10 times higher, represent-
ing an equivalent concentration of 1% or 5 mg/mL, signiﬁcant
loss in sensitivity is observed for eptiﬁbatide main impurity.
When peptide analysis is involved, low concentration
material appears to be difﬁcult to recover from the high
pressure LC system used along with sub-2 mm columns,
Figure 2
(A) Example of a chromatographic separation of atracurium besylate stereoisomers using an Agilent Technologies Zorbax Eclipse XDB-C18 50 mm 4.6 mm column with 1.8 mm
particle, using a potassium phosphate buffer–acetonitrile–methanol gradient at a ﬂow rate of 1.0 mL/min and UV detection at 280 nm.
(B) Example of a chromatographic separation of a degraded solution of cis–cis atracurium besylate exposed to a temperature of 80 1C for 60 min. The same chromatographic conditions
as those used in (a) were used. The peak eluting at 1.6 min corresponds to laudanosine (RRT¼0.27); the peak eluting at 7.4 min corresponds to monoacrylate laudanosine besylate
(RRT 1.26).
(C) Separation of a peptide from phenol preservative in a multi-dose formulation. Experimental conditions: Waters Acquity UPLCs BEH C18 column (50 mm 2.1 mm, with 1.7 mm
hybrid silica particles), using a mobile phase gradient with 0.1% aqueous phosphoric acid and acetonitrile in 4 min, at a ﬂow rate of 0.6 mL/min, with an injection volume of 1 mL and
detection wavelength at 220 nm. Solution concentration: 50 mg/mL.
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Table 1 Dosage of an octapeptide in a multi-strength drug product formulation.
Octapeptide formulation Speciﬁcations
(lg/mL)
Dosage release testing
(lg/mL)
Dosage testing by UPLC
(lg/mL) Difference (%)
Unidose low-strength batch #1 45–55 51 42 17.6
Multidose batch #2 180–220 209 206 1.4
Unidose high-strength batch #3 450–550 521 517 0.8
Figure 3 Impurity proﬁling of eptiﬁbatide drug substance by UPLC.
Experimental conditions: Phenomenex Kinetex C18 column (100 mm 2.1 mm, with 1.7 mm core-shell particles) using a mobile phase
gradient with diluted triﬂuoroacetic acid and acetonitrile, at a ﬂow rate of 0.5 mL/min, with an injection volume of 1 mL and detection
wavelength at 220 nm. Solution concentration of eptiﬁbatide: 500 mg/mL
(1) Eptiﬁbatide spiked with 0.5 mg/mL of its main impurity, which elutes after 5.38 min.
(2) Under the same conditions, eptiﬁbatide main impurity injected alone at 0.5 mg/mL cannot be detected.
(3) Eptiﬁbatide main impurity injected at 5 mg/mL can be barely detected with a signal-to-noise ratio of 2:1.
M.-J. Rocheleau et al.376limiting detectability and method sensitivity. On-system
adsorption of a small amount of peptide is suspected, leading
to a loss in sensitivity at low concentration. Results from the
analysis of octreotide acetate and Eptiﬁbatide have indicated
that response signal is lost when injecting only a few
nanograms of peptide. Although potential adsorption sites
could not be clearly identiﬁed, it is suspected that the low
porosity column frits used with sub-2 mm stationary phases
may be involved. Low porosity 0.2 mm column frits tend to
clog more easily than larger pore 0.5–2 mm frits used with
conventional LC columns, especially when analyzing biologi-
cal molecules and samples with complex matrices.4. Conclusion
Sub-2 mm column technology and high-pressure LC systems
can advantageously be used in challenging analyses with
signiﬁcant gain in speed, without sacriﬁcing separation efﬁ-
ciency and resolution. Useful mostly in the early phases of
drug development until very recently, application to late stage
pharmaceutical development and quality control is becoming
increasingly important as exempliﬁed here by several applica-
tions. When fast liquid chromatography is involved, sub-2 mmcolumn technology and high-pressure LC have been particu-
larly successful in purity analysis of hydrophobic drug sub-
stances, requiring high-resolving power and a rapid mobile
phase gradient.
Although not always straightforward as any new technol-
ogy has its own limitations, transfer of methodologies from
conventional LC to small particle size column LC is likely to
become increasingly important with the increased availability
of high pressure systems in quality control laboratories and
wider range of sub-2 mm stationary phases. Unfortunately
when biological molecules and samples are involved, the
limitations of the fast LC technology can seriously outweigh
the gain in efﬁciency. Low porosity column frits are more
prone to clog easily, requiring additional care in ﬁltering
mobile phases and sample preparation. Sensitivity issues may
also be encountered, limiting the applicability of sub-2 mm
column technology in the routine analysis of peptides; con-
ventional LC being then a more reliable and robust option.
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